anesthesia glp-1 news Are Serious Risks of Semaglutide and Other Agonists Under-Recognized? Case Reports of Retained Solid Gastric Contents in Patients Undergoing Anesthesia GLP-1 RA guidance roundup Study Challenges Seven-Day Hold on

If you stop taking them, appetite often returns to previous levels

A recent study shows people with obesity taking GLP-1 drugs are 20% less likely to suffer a cardiovascular event, and studies are under way for their use to treat the liver disease non-alcoholic steatohepatitis, as well as the neurodegenerative conditions Parkinsons and Alzheimers

About this article Cite this article Lu, Z., Liu, N., Huang, H

Biomolecules 9(9):389 Lakshmanan Y et al (2024) Lycium barbarum glycopeptide promotes neuroprotection in ET-1 mediated retinal ganglion cell degeneration

Understanding why these changes happen and what can support the skin through them can help women feel confident and informed throughout their weight-loss journey